Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHPA opposes irradiation

This article was originally published in The Tan Sheet

Executive Summary

The American Herbal Products Association submits a letter Dec. 14 to FDA's Center for Food Safety and Applied Nutrition requesting the agency deny a food-additive petition that would allow the use of ionizing irradiation on dietary supplements and dietary ingredients. The petition, submitted by Steris Corp in 2003, proposed that food-additive regulations be amended to provide for the safe use of ionizing radiation for the control of microbial contamination on dietary supplements and dietary ingredients, up to a maximum absorbed dose of 30 kGy (1"The Tan Sheet" Oct. 1, 2007, p. 6). AHPA proposed limiting ionizing radiation for supplements to 30 kGy, while the petition suggests the limit be from 3 to 30 times higher than currently allowed for all but two food categories. Irradiation currently is allowed in the U.S. for 11 food categories...

You may also be interested in...

Israelsen GMP Tips: Watch “Wild Card” Law, Use CoA As Legal Documents

Enforcement actions brought by the Federal Trade Commission against dietary ingredient companies that provide false or misleading certificates of analysis to supplement manufacturers could be an effective mechanism for assuring supply quality, according to Utah Natural Products Alliance Executive Director Loren Israelsen

EU Firsts Beckon For Olumiant In Dermatitis & Orfadin For AKU

The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.

Roche Bulks Up In NLRP3 With €380m Inflazome Buy

Having acquired Jecure Therapeutics and its preclinical portfolio of NLRP3 inhibitors just under two years ago, the Swiss giant has swooped in to buy Dublin-based Inflazome and expand its presence in a hot field of inflammatory research.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts